{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:07:43Z","timestamp":1792757263218,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T00:00:00Z","timestamp":1527033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,14]]},"DOI":"10.1093\/cid\/ciy432","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T11:09:12Z","timestamp":1526382552000},"page":"1132-1138","source":"Crossref","is-referenced-by-count":20,"title":["Twenty-first Century Cures Act and Antimicrobial Susceptibility Testing: Clinical Implications in the Era of Multidrug Resistance"],"prefix":"10.1093","volume":"67","author":[{"given":"Romney M","family":"Humphries","sequence":"first","affiliation":[{"name":"Accelerate Diagnostics, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Hindler","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Jane Ferraro","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Mathers","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease and International Health, Department of Medicine, University of Virginia Health System, Charlottesville"},{"name":"Clinical Microbiology Laboratory, Department of Pathology, University of Virginia Health System, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,23]]},"reference":[{"key":"key\n\t\t\t\t20180914010350_CIT0001","volume-title":"Antimicrobial resistance: a global report on surveillance","author":"World Health Organization (WHO)","year":"2014"},{"key":"key\n\t\t\t\t20180914010350_CIT0002","first-page":"1","volume-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention (CDC)","year":"2013"},{"key":"key\n\t\t\t\t20180914010350_CIT0003","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/cid\/cix893","article-title":"Carbapenemase-producing organisms: a global scourge","volume":"66","author":"Bonomo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180914010350_CIT0004","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-017-0153-2","article-title":"Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: a review","volume":"6","author":"Lashinsky","year":"2017","journal-title":"Infect Dis Ther"},{"key":"key\n\t\t\t\t20180914010350_CIT0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijantimicag.2017.12.020","article-title":"Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180914010350_CIT0006","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ijantimicag.2016.11.021","article-title":"Revival of old antibiotics: needs, the state of evidence and expectations","volume":"49","author":"Zayyad","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180914010350_CIT0007","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180914010350_CIT0008","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/cid\/cix942","article-title":"Carbapenem-resistant Enterobacteriaceae detection practices in California: what are we missing","volume":"66","author":"Humphries","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180914010350_CIT0009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/cid\/ciw201","article-title":"Emerging resistance, new antimicrobial agents\u2026but no tests! The challenge of antimicrobial susceptibility testing in the current US regulatory landscape","volume":"63","author":"Humphries","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180914010350_CIT0010","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1128\/JCM.00635-16","article-title":"Impact of delays between Clinical and Laboratory Standards Institute and Food and Drug Administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae","volume":"54","author":"Bartsch","year":"2016","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180914010350_CIT0011","volume-title":"21st Century Cures Act. HR 34, 114th Congress","year":"2015"},{"key":"key\n\t\t\t\t20180914010350_CIT0012","volume-title":"FDA-recognized antimicrobial susceptibility test interpretive criteria","author":"US Food and Drug Administration (FDA)"},{"key":"key\n\t\t\t\t20180914010350_CIT0013","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"key\n\t\t\t\t20180914010350_CIT0014","article-title":"Class II special controls guidance document: antimicrobial susceptibility test (AST) systems","author":"US Food and Drug Administration (FDA), Center for Devices and Radiological Health","year":"2009"},{"key":"key\n\t\t\t\t20180914010350_CIT0015","volume-title":"Cubicin(R) for injection prescribing information","author":"Merck & Co","year":"2017"},{"key":"key\n\t\t\t\t20180914010350_CIT0016","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40121-017-0149-y","article-title":"Anticipating the unpredictable: a review of antimicrobial stewardship and Acinetobacter infections","volume":"6","author":"Wenzler","year":"2017","journal-title":"Infect Dis Ther"},{"key":"key\n\t\t\t\t20180914010350_CIT0017","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts. CLSI document M27-S4","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"key":"key\n\t\t\t\t20180914010350_CIT0018","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","article-title":"Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study","volume":"16","author":"Liu","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180914010350_CIT0019","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1111\/1469-0691.12070","article-title":"High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality","volume":"19","author":"Capone","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180914010350_CIT0020","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/528712","article-title":"Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint","volume":"46","author":"Tam","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180914010350_CIT0021","volume-title":"Coordinated development of antimicrobial drugs and antimicrobial susceptibility devices: draft guidance for industry and Food and Drug Administration staff","author":"US Food and Drug Administration (FDA)","year":"2017"},{"key":"key\n\t\t\t\t20180914010350_CIT0022","volume-title":"Epidemiological cutoff values for antifungal susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016","edition":"1st ed"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/7\/1132\/25722113\/ciy432.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T02:04:36Z","timestamp":1571364276000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/7\/1132\/5001711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,23]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,5,23]]},"published-print":{"date-parts":[[2018,9,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy432","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10,1]]},"published":{"date-parts":[[2018,5,23]]}}}